{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=44&state=Virginia", "query": { "state": "Virginia", "city": "Fairfax", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 2554, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=45&state=Virginia&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=43&state=Virginia&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T18:55:23.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01835080", "title": "Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Arterial Hypertension", "Obstructive Sleep Apnea" ], "interventions": [], "intervention_types": [], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-04", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 1, "location_summary": "Falls Church, Virginia", "locations": [ { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835080" }, { "nct_id": "NCT05199870", "title": "MDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hip Arthritis", "Hip Disease", "Hip Fractures", "Hip Injuries", "Hip Pain Chronic" ], "interventions": [ { "name": "RingLoc Bipolar Acetabular Cup", "type": "DEVICE" }, { "name": "Endo II Femoral Head", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Zimmer Biomet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2026-03-10", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 1, "location_summary": "Falls Church, Virginia", "locations": [ { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199870" }, { "nct_id": "NCT04320888", "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent WHO Grade 2 Glioma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory WHO Grade 2 Glioma", "Wilms Tumor" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1, "start_date": "2021-05-03", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 172, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04320888" }, { "nct_id": "NCT05375994", "title": "Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "KRAS Activating Mutation", "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplasm of Lung", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "avutometinib (VS-6766) and adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-08-01", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 8, "location_summary": "San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05375994" }, { "nct_id": "NCT06555744", "title": "A Study of ZW191 in Participants With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ZW191", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zymeworks BC Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2024-10-30", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Columbus, Ohio • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06555744" }, { "nct_id": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced (Inoperable) or Metastatic Breast Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 893, "start_date": "2021-05-10", "completion_date": "2029-08-14", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 40, "location_summary": "Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Napa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04862663" }, { "nct_id": "NCT02488967", "title": "Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Adenocarcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 782, "start_date": "2015-07-26", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 1286, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 815 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02488967" }, { "nct_id": "NCT02684032", "title": "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 141, "start_date": "2016-06-14", "completion_date": "2022-01-19", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02684032" }, { "nct_id": "NCT00354835", "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adult Rhabdomyosarcoma", "Childhood Alveolar Rhabdomyosarcoma", "Childhood Botryoid-Type Embryonal Rhabdomyosarcoma", "Childhood Embryonal Rhabdomyosarcoma", "Localized Childhood Soft Tissue Sarcoma", "Rhabdomyosarcoma", "Sarcoma", "Stage I Adult Soft Tissue Sarcoma AJCC v7", "Stage II Adult Soft Tissue Sarcoma AJCC v7", "Stage III Adult Soft Tissue Sarcoma AJCC v7" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 481, "start_date": "2006-12-26", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2023-01-31", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 196, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00354835" }, { "nct_id": "NCT04596150", "title": "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Breast Neoplasms", "Breast Neoplasms, Triple-Negative", "Breast Cancer", "Breast Neoplasms, Hormone Receptor Positive/HER2 Negative" ], "interventions": [ { "name": "CX-2009", "type": "DRUG" }, { "name": "CX-072", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2020-12-29", "completion_date": "2023-06-02", "has_results": false, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-10-27T18:55:23.215Z", "location_count": 27, "location_summary": "La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04596150" } ] }